Safety, Tolerability and Pharmacokinetics/Pharmacodynamics (PK/PD) of SHR-1603 in Subjects With Advanced Malignancies

Summary

SHR-1603-I-101 is an single-arm, open-label, dose finding phase I clinical trial of SHR-1603 in subjects with advanced solid tumor or relapsed/refractory malignant lymphoid diseases. The study drug will be administered by intravenous infusion.

Timeline

Start

2018-11-13

Primary completion

2019-04-04

Completion

2021-10

Outcome

Outcome not reported

Stopped (Business): “Business Decision”

Drugs

Indications